URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)
Stock Stats
News
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® [Yahoo! Finance]
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
Form SC 13D/A UroGen Pharma Ltd. Filed by: Pontifax Management III G.P. (2011) Ltd.
Form SC 13G/A UroGen Pharma Ltd. Filed by: Point72 Asset Management, L.P.
Form SC 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A UroGen Pharma Ltd. Filed by: GREAT POINT PARTNERS LLC
Form SC 13G/A UroGen Pharma Ltd. Filed by: MENORA MIVTACHIM HOLDINGS LTD.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.